Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2024 (2024-12-31): -913.07%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-613.88%
RETURN ON EQUITY (ROE) AVG 3Y
-384.40%
RETURN ON EQUITY (ROE) AVG 5Y
-222.13%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Evolus, Inc.
Market Cap
$490.62M
Return on Equity (ROE)
N/A
TTM Avg
-613.88%
3Y Avg
-384.40%
5Y Avg
-222.13%
Market Cap
$486.87M
Return on Equity (ROE)
19.28%
TTM Avg
28.37%
3Y Avg
24.29%
5Y Avg
382.68%
Market Cap
$497.40M
Return on Equity (ROE)
-36.79%
TTM Avg
-82.52%
3Y Avg
-55.07%
5Y Avg
-25.96%
Market Cap
$479.39M
Return on Equity (ROE)
1.65%
TTM Avg
-27.02%
3Y Avg
-39.92%
5Y Avg
-33.78%
Market Cap
$472.82M
Return on Equity (ROE)
-8.21%
TTM Avg
-32.76%
3Y Avg
-79.80%
5Y Avg
-71.61%
Market Cap
$474.21M
Return on Equity (ROE)
-24.02%
TTM Avg
-22.16%
3Y Avg
-34.88%
5Y Avg
-37.32%
Market Cap
$472.52M
Return on Equity (ROE)
8.25%
TTM Avg
6.54%
3Y Avg
3.79%
5Y Avg
3.91%
Market Cap
$503.89M
Return on Equity (ROE)
-37.94%
TTM Avg
-63.13%
3Y Avg
-60.30%
5Y Avg
-47.34%
Market Cap
$472.58M
Return on Equity (ROE)
-9.69%
TTM Avg
-30.79%
3Y Avg
-49.02%
5Y Avg
-53.00%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | $490.62M | N/A | -613.88% | -384.40% | -222.13% |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.87M | 19.28% | 28.37% | 24.29% | 382.68% |
| Oculis Holding AG (OCS)vs › | $497.40M | -36.79% | -82.52% | -55.07% | -25.96% |
| Arvinas, Inc. (ARVN)vs › | $479.39M | 1.65% | -27.02% | -39.92% | -33.78% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.82M | -8.21% | -32.76% | -79.80% | -71.61% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $474.21M | -24.02% | -22.16% | -34.88% | -37.32% |
| Kamada Ltd. (KMDA)vs › | $472.52M | 8.25% | 6.54% | 3.79% | 3.91% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.89M | -37.94% | -63.13% | -60.30% | -47.34% |
| Cerus Corporation (CERS)vs › | $472.58M | -9.69% | -30.79% | -49.02% | -53.00% |
| 908 Devices Inc. (MASS)vs › | $509.64M | -27.20% | -44.25% | -32.03% | -24.61% |
ROE
N/A
ROA
-13.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2024-12-31 | -913.07% |
| 2024-09-30 | -941.60% |
| 2024-06-30 | -275.52% |
| 2024-03-31 | -325.34% |
| 2022-12-31 | -402.25% |
| 2022-09-30 | -271.82% |
| 2022-06-30 | -167.69% |
| 2022-03-31 | -105.15% |
| 2021-12-31 | -57.17% |
| 2021-09-30 | -143.04% |
| 2021-06-30 | -123.76% |
| 2021-03-31 | -587.73% |
| 2020-09-30 | -190.42% |
| 2020-06-30 | -188.87% |
| 2020-03-31 | -157.80% |
| 2019-12-31 | -113.31% |
| 2019-09-30 | -516.15% |
| 2019-06-30 | -176.81% |
| 2019-03-31 | -68.58% |
| 2018-09-30 | -31.57% |
| 2018-06-30 | -54.78% |
| 2018-03-31 | -12.78% |
